Sagimet Biosciences (SGMT) Cash from Operations: 2023-2024
Historic Cash from Operations for Sagimet Biosciences (SGMT) over the last 2 years, with Sep 2024 value amounting to -$19.6 million.
- Sagimet Biosciences' Cash from Operations fell 404.49% to -$19.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$38.5 million, marking a year-over-year change of. This contributed to the annual value of -$42.4 million for FY2024, which is 78.55% down from last year.
- As of Q3 2024, Sagimet Biosciences' Cash from Operations stood at -$19.6 million, which was down 247.34% from -$5.6 million recorded in Q2 2024.
- Over the past 5 years, Sagimet Biosciences' Cash from Operations peaked at -$3.9 million during Q3 2023, and registered a low of -$19.6 million during Q3 2024.
- For the 2-year period, Sagimet Biosciences' Cash from Operations averaged around -$7.9 million, with its median value being -$6.2 million (2024).
- The largest annual percentage gain for Sagimet Biosciences' Cash from Operations in the last 5 years was 12.37% (2024), contrasted with its biggest fall of 404.49% (2024).
- Quarterly analysis of 2 years shows Sagimet Biosciences' Cash from Operations stood at -$7.1 million in 2023, then crashed by 404.49% to -$19.6 million in 2024.
- Its last three reported values are -$19.6 million in Q3 2024, -$5.6 million for Q2 2024, and -$6.2 million during Q1 2024.